Precigen presents new data supporting the safety, clinical activity, expansion and persistence of prgn-3006 ultracar-t® at the 62nd ash annual meeting and exposition

Germantown, md., dec. 7, 2020 /prnewswire/ -- precigen, inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced at the 62nd ash annual meeting and exposition (abstract 2864) clinical progress...

PGEN Ratings Summary

PGEN Quant Ranking